Omnaris Versus Levocetirizine Phase 4 Study

randomized, open-label, three arm, parallel group, multi-center study

Inclusion criteria

• Allergic rhinitis patients aged ≥ 18 years (with a history of AR of 1 years or longer)
• Moderate to severe patient according to ARIA guideline
• To have a demonstrated positive skin prick test or other serologic tests to at least 1 allergen.
• Subjects who complete the subject diary(S) at least 70%.

Exclusion criteria

• Nasal pathology, including nasal polyps, clinically relevant respiratory tract malformations, recent nasal biopsy (within 60 days), nasal trauma, nasal surgery, atrophic rhinitis, rhinitis medicamentosa (within 60 days), asthma requiring corticosteroid treatment
• Hypersensitivity to corticosteroid and/or hydroxyzine
• Hypersensitivity to galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption
• A history of respiratory tract infection or disorder within 2 weeks of the screening visit or had a respiratory tract infection during baseline
• Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of β-agonists
• Treated with systemic corticosteroids (within 8 weeks of study initiation) or topical corticosteroids (> 1% hydrocortisone, within 4 weeks of study initiation) or antibiotics (within 2 weeks of first visit)